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     大村清隆，塚本泰司
ANTIPROLIFERATIVE EFFECT OF INTERFERON－ALPHA ON
HU．MAN RENAL CELL CARCINOMA IN CLONOGENIC ASSAY
一SINGLF．， AND COMBINATION EFFECT X？VITH
  CAttCER CHEMOTHERAPEUTiC AGENT一
 Kiyotaka OHMuRA and Taiji TsuKAMoTo
・F・’・m’lie DePartme」：t ｛ゾu・畠・1・g＞・．＆ipp・r・M8勲κ吻6
   With human tumor c1Qnogenic assay， the direct antiproliferative activity of recombinant human
leukocyte interferon alpha（IFN一α）was investigated on human renal cell carcinornas（RGGs）， which
consisted of a human RCC cellline（ACHN）， two human RG（〕xenografts and fifteell primary R（〕Cs．
The combination effec亡。．f IFN一αwith a cancer chemo亡herapcutic agent was stud孟ed， as we1】， with the
aSSay systeエn．
   IFN一αshowed a dose－depe璽dent n・．ntiproliferative activity against tlle human RCCs． The cIonaI
gr◎wth of ACHN cell line w鋪inhibited by less than 50％．at t｝ユe concentration of l，0001U／ml． Two
xenografts had a different sensitivitiy to IFN一α， in which the percent colony fbrmation was less than 20％
in RGC鱒3 at the concentra亡ioll of 100－100ン0001U／皿1， wh三亙e in RCC－4 more than 50％ evcn at the high
concentr’ation of 10，0001U／mL
   In 15 primary tumors obtained at surgery， two types of response to IFN一αwere dcmonstrated．
One was the response in which the colony f（〕rmation was inhibi亡ed ill a dose－dependcnt manncr as an
increment of IFN一αconcentration， and the other ill which the colony formation was l／ot su冊ciently
inhib｛ted evcu at the｝high concentration of IFN一α． The dose－dependent inhib三tioll of colony tbrmation was
demonstrated in 100ut of l 5 specimens（66．7％）． Whell the colony fbrmation suppressed to lcss than 50％
of control was considered to be sensitive to IFN一α，6．7％of these 15primary tumors were sα1sitive to IFN一
α．at 1001U／m1，20．0％at 1，0001U／皿1 and 20，0％at】0，0001U／ml．
   Cornbination effects of IFN－ct and with each of｛bur di飴rent cancer chemotherapeutic age飢s（villblastine，
adriamycin， methotrexate，5－fiuorouracil）were investigated on the AGHN cell llne． Every combination
type produced a subadditive or synergistic combination effect． In particular， the combination of IFN一α
with vinblastine of more than O，1μg／ml concentration yielded a gombinatiOn effect of statistical
slgni丘cance（p《：0．OOI）． Even against． premary tumors， the comb三nation of IFN一αwith vinblastinc
sllowed a synergistic e．ffect in one out of e▽ery three tumors． These results suggested that the combinatioll
o£IFN一α with a cancer chemotherapeutic agent、vou正d enhance the ciinical．effect of IFN一αa玉one in only
     ロ           コ             のa certaln sltuahon．
                                              （Acta urol． JPn．35：737－747，1989）
K6y words：Renal ce11 carcilloma， Humah tumor clon‘〕genic assay， Interferonor， Canccr
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Fig． 1． Changes in activity of rlFN－crA during
    incubation period， Each point represents
































Table 1． Assessment of drug combination effeets in clonogenic assay
Synergistic A tt”B＞ （A） × C B） 〉 ［A＋B）
Additive A｝I B＞ （A） × ［B） ＝ ［A＋B）
Subadditive ［A）， （B］ 〉 CA＋Bj 〉 CA］ × （B）
Interference ［A］〉 （A十B） ＞CB］ 1．？ （A） × C B］
              or （B） 〉 （A十B） 〉 （A） 1．） （A） × ［B）




：surviving rate for individual drugs
： surviving rate for drugs used in combination
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Eeeh poJnt represents an average ot three dishes．
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Fig．2． Effect of recomb量nant inter蝕on・αon
    colony formation rate of established
    renal cell carcinoma cell line， ACHN．
    Each point represents an average of
    three’ diches． Bars mean standard
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Fig． 3． Effect of recombinant interferon－a on
    colony formation rate of xenograft
    human renal cell carcinome （RCC－3＆4）．
    Each point represents an average of
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Fi．cr． 4． Effect of recombinant interferon－cr on
   colony formation rate of human renal
    cell carcinoma specimens． Each point






























Plating efficiency of control dishes in clonogenic assay and histological
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1） Plating efficiency ： number of coloniesfnumber of cells plated； an average of three control dishes．
2＞ Alveolar：Alveolar type， Papillary： Papillary type， Tubular l Tubular type
3） Clear： Clear cell subtype， Granular： Granular subtype， Mixed： Mixed subtype
4） alExpansive type， B l Intermediate type
Table 3． Sensitiviy to rlFN－crA in clonogenic assay for hurrian renal cell carcinomas
IFN concentration and
colony forrnation rate．







































































































































Sensitivity Rate1／15（6．70／e） 3／15（20．0％） 2／10（20．0％）1／3 （33．30／o） 0／6（oO／o＞
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Table 4． Result of multiple regression analysis







































Table 5． EDso of rlFN－exA for IFN－siensitive
      renal cell carcinorna cells in clono－
























Table 6．Interaction of rlFN一αA and． chemotherapeutic drugs on colony formation
of cell line， ACHN















〔A〕 〔B〕 〔A÷B〕 〔A〕x〔B〕
VBL
0．01（μ9／m1）63．8±12．7 25．3±8．821．8±10．2SubadditiveN．S．
0．1 66．7±16．2 4．9±2．3 22．8±11．1SynergisticP＜0．001
1．0 19．7±3．8 2．5±0．7 6．7±3．1 SynergisticP〈0．001
10 16．7±5．8 0．7±0．1 5．7±3．1 SynergisticP＜0．001
rlFN・αA ADM
1，000（IU／m1）：0．01（μ9／m1）106 ±75，017．2±9．4 36．3±29．8SynergisticN．S，
34．2±14．40．1 107 ±35．414，0±5．6 36．6±19．6SynergisticN，S．
1．0 37．8±6．0 10。3±5．9 12．9±5．8 SynergistlcN，S．
10 30．7±8．6 4．7±1．9 10．5±5．3 Syhergist｛cN．S．
MTX
0，5（μ9／ml） 130 ±69．818．5±7．8 44，5±30．3SynergisticN．S。
5．0 61．0±14．9 11．5±6．6 20．9±10．2SynergisticN．S．
50 16．5±2．2 8．6±6．4 5．6±2．5 SubadditiveN．S．
5－FU
0．6（μ9／m1） 84．4±59．7 28．3±7．828．9±23．7SynergisticN．S．
6．0 44．8±18．6 10．7±2．1 15．3±9．1 SynergisticN．S．
60 27。4±6．7 3．2±1．4 9．4±4．5 SynergisticN．S，
a） P values are reported only for differences between “expectedi’ and “observed” colony formation rate


























































Tablc フ。Jnteraction， of rlFN－evA and vinblastine on colony forrnation
of human renal ce11 carcinoma obtained from surgery
Observed colony
formation rate
Case with rlFN－aA alone
（％Mean±SE）















 （A） × （B）
Combined P c）
 effect value
1 H．K． （1，000）a） 80．1
         ±11．7
（o．1）b） 7s．o
    ± 7．9
（1．0） b） 72．7











2 T．T． 〈1，000）a） 66．6
         ±22．6
（o．Ol）b） 91．s
    ±11．4
（o．1）b） 64．s











3 s．K． （1，000）a） loo
         ±19．1
（o．1）b） 7s．6






a） Used concentration of rlFN－aA （IUIme）．
b） Used concentration of VBL （” g／me）．
c） P values are reported only for differences between “expected” and “observed” colony fermation rate
 that indicate sta亡istlcally significant drug synergy or an亡agonism













































 しかし，マウスでのin vivo抗腫瘍実験では， in
vitroではIFN－resistantである3Cl・8細胞に対し



























































い，rIFN一αA と VBL， vincr三stine， vindesine，
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